Year: 2015
Type: article
Abstract: Background: Left atrial appendage (LAA) closure with the Watchman device and AMPLATZER Cardiac Plug (ACP) has been shown to be a safe and effective alternative to oral anticoagulant therapy.In real-world practice in Latvia, LAA closure is preformed in AF patients with high stroke and bleeding risk, distinction from the two randomized controlled trial of device closure for patients with atrial fibrillation.LAA 2015 Objectives: The purpose of the Latvian LAA clo prevention in highrisk patients with atrial fibrillation (AF).Methods: This is a single centre prospective non-randomized longitudinal cohort study of LAA closure with the Watchman device and ACP during five years.The registry collected data about clinical condition, efficacy and safety events (ischemic/hemorrhagic stroke, death, systemic embolism, device thrombosis or embolization, pericardial tamponade) from May 2010 to September 2015.Results: In total 29 LAA closure cases were studied.Successful LAA closure was achieved in 96.6% of cases (n=28).The Watchman device was implanted in 50% and the ACP in 50% of cases.Mean CHA2DS2-VASc score was 6.3 (1.6) and HAS-BLED score -3.3 (1.0).The main indication for closure was recurrent ischemic stroke and low compliance with warfarin usage.Serious peri-procedural safety events (device embolization of a Watchman device) occurred in one patient (n=1).Mean follow-up time was 38 (19.8) months, patients followed n=26.During 45 post-procedural days there was one (n=1) device thrombosis without clinical sequelae.After day 45, ischemic stroke occurred in LAA 2015 AbstractsHow to Close the Left Atrial Appendage http://www.csi-congress.org/laaAnticoagulation for stroke prevention in atrial fibrillation is difficult in clinical practice -with Coumadin and also with NOACS.Left atrial appendage closure has been shown to be superior to anticoagulation regarding stroke prevention, bleeding complications and even mortality.Several devices now have CE mark and/or FDA approval and many others are already in clinical trials.LAA Frankfurt is a 2-day course, designed to give attendees an overview on all aspects of this treatment modality.During the course we cover clinical studies and demonstrate how to perform the procedure step by step and how to prevent and manage complications.Live case transmissions are a core of this course and allow direct attendee-operator interaction to maximize the learning experience.LAA 2016 will take place November 18-19, in Frankfurt, Germany.If you would like to join this year, please visit our website for more information
Author: Horst Sievert
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4236505190